J Beltman
Overview
Explore the profile of J Beltman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beltman J, Erickson J, Martin G, Lyons J, Cook S
J Biol Chem
. 1999 Jan;
274(6):3772-80.
PMID: 9920930
Lysophosphatidic acid (LPA) stimulates the c-Fos serum response element (SRE) by activating two distinct signal pathways regulated by the small GTPases, Ras and RhoA. Ras activates the ERK cascade leading...
2.
Cook S, Beltman J, Cadwallader K, McMahon M, McCormick F
J Biol Chem
. 1997 May;
272(20):13309-19.
PMID: 9148952
Stimulation of Rat-1 cells with lysophosphatidic acid (LPA) or epidermal growth factor (EGF) results in a biphasic, sustained activation of extracellular signal-regulated kinase 1 (ERK1). Pretreatment of Rat-1 cells with...
3.
Cadwallader K, Beltman J, McCormick F, Cook S
Biochem J
. 1997 Feb;
321 ( Pt 3):795-804.
PMID: 9032468
The extracellular signal-regulated protein kinase (ERK) and Jun N-terminal kinase (JNK) signalling cascades transduce signals from the cell cytoplasm to the nucleus, where they regulate gene expression. The activation of...
4.
Beltman J, McCormick F, Cook S
J Biol Chem
. 1996 Oct;
271(43):27018-24.
PMID: 8900190
The role of protein kinase C (PKC) in inflammation, mitogenesis, and differentiation has been deduced in part through the use of a variety of PKC inhibitors. Two widely used inhibitors...
5.
Butt E, Beltman J, Becker D, Jensen G, Rybalkin S, Jastorff B, et al.
Mol Pharmacol
. 1995 Feb;
47(2):340-7.
PMID: 7870042
To define essential interactions of cAMP with the catalytic sites of cyclic nucleotide phosphodiesterases (PDEs) and to begin to map the topology of the sites, we have tested a series...
6.
Beltman J, Becker D, Butt E, Jensen G, Rybalkin S, Jastorff B, et al.
Mol Pharmacol
. 1995 Feb;
47(2):330-9.
PMID: 7870041
To help define essential interactions of cGMP with the catalytic site, we tested a series of cGMP analogs as competitive inhibitors of each cyclic nucleotide phosphodiesterase (PDE) family known to...
7.
Beltman J, Sonnenburg W, Beavo J
Mol Cell Biochem
. 1993 Nov;
127-128:239-53.
PMID: 7935355
The cyclic nucleotide phosphodiesterases constitute a complex superfamily of enzymes responsible for catalyzing the hydrolysis of cyclic nucleotides. Regulation of cyclic nucleotide phosphodiesterases is one of the two major mechanisms...
8.
Butt E, Nolte C, Schulz S, Beltman J, Beavo J, Jastorff B, et al.
Biochem Pharmacol
. 1992 Jun;
43(12):2591-600.
PMID: 1321624
8-(p-Chlorophenylthio)-cGMP (8-pCPT-cGMP) and 8-bromo-cGMP were compared with respect to their chemical and biological properties in order to evaluate their potential as selective activators of cGMP-dependent protein kinase (cGMP-PK; EC 2.7.1.37)...
9.
Sandberg M, Butt E, Nolte C, Fischer L, Halbrugge M, Beltman J, et al.
Biochem J
. 1991 Oct;
279 ( Pt 2):521-7.
PMID: 1659381
A newly designed cyclic AMP (cAMP) analogue, Sp-5,6-dichloro-1-beta-D- ribofuranosylbenzimidazole-3',5'-monophosphorothioate (Sp-5,6-DCl-cBiMPS), and 8-(p-chlorophenylthio)-cAMP (8-pCPT-cAMP) were compared with respect to their chemical and biological properties in order to assess their potential as...